mTORC1通路对抗B-ALL细胞的葡萄糖皮质体活性中的核心作用
Hiroshi Imanaga1,2, Yuichiro Semba1,3, Kensuke Sasaki1,2
1Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Blood neoplasia
|June 2, 2025
概括
葡萄糖皮质醇 (GCs) 通过抑制mTORC1信号来杀死B细胞急性淋巴细胞白血病 (B-ALL) 细胞. 瘤性mTORC1激活赋予了耐药性,突出了B-ALL治疗中的一个关键漏洞.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞死亡机制 细胞死亡机制
背景情况:
- 像甲这样的葡萄皮质激素 (GC) 在B细胞前体急性淋巴细胞白血病 (B-ALL) 治疗中至关重要.
- 驱动GC诱导的B-ALL细胞死亡的精确分子机制尚未完全理解.
研究的目的:
- 阐明B-ALL中葡萄糖皮质激素敏感性和耐药性的分子基础.
- 调查拉巴胺素复合体1 (mTORC1) 信号传递机械点在GC反应中的作用.
主要方法:
- 使用全基因组的CRISPR/CRISPR相关蛋白9 (CRISPR/Cas9) 脱落选器.
- 进行RNA测序以确定德克萨米他的基因.
- 实验涉及具有不同GC受体功能的B-ALL细胞系.
主要成果:
- 在B-ALL细胞中,GC抑制了拉巴胺复合体1 (mTORC1) 信号传递的机械标.
- 激活mTORC1信号传递会对GC产生抗性.
- 德克萨米他通过降低mTORC1的调节,促进自和损害蛋白质合成来诱导细胞死亡.
- 德克萨米他通过转录抑制mTORC1活动通过特定的目标基因.
结论:
- 在B-ALL中,GC敏感性是由激素刺激和激活PI3K-AKT-mTORC1通路的生长因子调节的.
- mTORC1信号传递是B-ALL中GC反应的关键决定因素.
- 了解这种途径可能会揭示对抗GC的ALL亚型的新治疗策略.
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
01:22PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
01:16TGF - β Signaling Pathway
7.7K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.7K
01:20The JAK-STAT Signaling Pathway
9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.3K
02:38Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K